علاج الإنفلونزا في الأطفال والمراهقين دون سن 18 عامًا

References

DOI: 10.1093/cid/ciy866

• Oseltamivir (tablets or oral suspension formulation) may be administered to all pediatric age groups with influenza, including premature infants.
• Duration of therapy for ambulatory children with uncomplicated influenza is 5 days.
• Zanamivir (inhalation) is FDA-approved for treatment of uncomplicated influenza in children aged ≥7 years.
• Dosing and duration of uncomplicated influenza is the same for all pediatric age groups (2 inhalations twice daily for 5 days).
• Peramivir is the only FDA-approved IV antiviral drug and is approved for early treatment of uncomplicated influenza in outpatients aged ≥2 years.
• Systematic reviews and meta-analyses of RCTs indicate that early initiation (within 2 days of illness onset) of antiviral treatment can reduce the duration of fever and symptoms, especially in nonasthmatic children; decrease the risk of otitis media in children; and reduce the risk of lower respiratory tract complications requiring antibiotics and of hospitalization in adults.